ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

12 May 2023 07:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

09 May 2023 06:30:35 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

03 May 2023 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

25 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

12 Apr 2023 06:30:43 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

06 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

27 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results

14 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

23 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

27 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

10 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

01 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

21 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

21 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

03 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers 

11 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

05 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

12 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

02 Sep 2022 07:00:00 By Nasdaq GlobeNewswire